BioLife Q3 total rev $28.1M (+31% YoY); net income $0.6M; raises cell processing guidance to $93-94M

BIOLIFE SOLUTIONS INC

2025-Q3 EPS reported -$0.33 revenue$77,429,000

Total Q3 revenue $28.1M (up 31% YoY); Cell Processing revenue $25.4M (up 33% YoY).
GAAP net income $0.6M vs loss $0.5M in Q3 2024; adjusted EBITDA $7.8M (28% of revenue).
Full-year Cell Processing revenue guidance raised to $93-94M (from $91-93M); total rev $95-96M excl. evo.
Completed sale of evo cold chain logistics on Oct 6 for $25.5M cash, streamlining to pure-play cell processing.
Cash and marketable securities $98.4M as of Sep 30; no evo proceeds included.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.